Roche OTC Business Review Raises Questions On Xenical Switch
Roche's decision to put its nonprescription business under review may indicate that a switch of its anti-obesity drug Xenical is unlikely
Roche's decision to put its nonprescription business under review may indicate that a switch of its anti-obesity drug Xenical is unlikely